Lumicell is a pioneering company based in Wellesley, MA that is revolutionizing breast cancer surgery with its investigational fluorescence imaging technology. Their system is designed to provide real-time illumination of residual breast cancer during lumpectomy surgery, assisting in the detection of cancerous tissue within the lumpectomy cavity. With the potential to transform the current landscape of breast cancer surgery, Lumicell's transformative technology aims to evolve the standard of care in cancer surgery.
Lumicell's innovative approach has garnered attention and recognition, with their co-founder Moungi Bawendi being awarded the Nobel Prize in Chemistry for his expertise in optics, fluorescent molecules, and tissue imaging. The company has also made significant strides in gaining regulatory approval, with the FDA accepting and prioritizing their New Drug Application for the LUMISIGHT Optical Imaging Agent and their Premarket Approval application for the Lumicell Direct Visualization System. Lumicell's commitment to advancing cancer surgery is further demonstrated by their recent appointment of Brent Palmisano as Chief Commercial Officer, as they prepare for the market launch of their groundbreaking technology.
Generated from the website